Renal Ischemia-reperfusion Leads to Hypertension and Changes in Proximal Tubule Na Transport and Renin-angiotensin-aldosterone System: Role of NADPH Oxidase
Overview
Biology
Physiology
Authors
Affiliations
Acute renal injury (AKI) is a risk factor for the development of hypertension, which involves oxidative stress, changes in Na handling, and the intrarenal renin-angiotensin-aldosterone system (RAAS) as underlying mechanisms. We investigated in rats whether renal ischemia-reperfusion (IR) leads to changes in the proximal tubule ATP-dependent Na transport and the intrarenal content of RAAS components, as well as the role of NADPH oxidase. Rats weighing 300-350 g were submitted to AKI by bilateral IR (n = 25). After IR injury, the animals were followed up for 4 weeks. One part (n = 7) received daily treatment with the NADPH oxidase inhibitor apocynin (100 mg/kg, drinking water), while another part (n = 9) received apocynin 24 h before and after IR. One group was submitted to sham surgery (n = 8). Four weeks after IR, the rats presented elevated systolic blood pressure, as well as increased lipid peroxidation, NADPH oxidase activity, (Na+K)ATPase activity, and upregulation of type 1 angiotensin II receptor in the renal cortex. On the other hand, there was a decrease in Na-ATPase activity and downregulation of the isoforms 1 and 2 of the angiotensin-converting enzyme, type 2 angiotensin II receptor, and of the α and ε isoforms of protein kinase C. Most of these alterations was prevented by both apocynin treatment protocols. Thus, we conclude that AKI-induced by IR may induce changes in proximal tubule ATPases and RAAS components compatible with renal Na retention and hypertension. These data also indicate that the NADPH oxidase represents a key factor in the origin of these alterations.
Metabolic Chaos in Kidney Disease: Unraveling Energy Dysregulation.
Gupta P, Zhu S, Gui Y, Zhou D J Clin Med. 2024; 13(22).
PMID: 39597916 PMC: 11594442. DOI: 10.3390/jcm13226772.
Abdelsalam H, Samy A, Mosaleem E, Abdelhamid M Sci Rep. 2024; 14(1):26888.
PMID: 39505968 PMC: 11541720. DOI: 10.1038/s41598-024-77094-2.
The Molecular Mechanism and Therapeutic Strategy of Cardiorenal Syndrome Type 3.
Liu Y, Guan X, Shao Y, Zhou J, Huang Y Rev Cardiovasc Med. 2024; 24(2):52.
PMID: 39077418 PMC: 11273121. DOI: 10.31083/j.rcm2402052.
Revesz C, Kaucsar T, Godo M, Bocskai K, Krenacs T, Mocsai A Int J Mol Sci. 2024; 25(5).
PMID: 38474193 PMC: 10932292. DOI: 10.3390/ijms25052948.
Carneiro de Oliveira K, Wei Y, Repetti R, Meth J, Majumder N, Sapkota A Am J Physiol Renal Physiol. 2023; 326(2):F265-F277.
PMID: 38153852 PMC: 11207546. DOI: 10.1152/ajprenal.00154.2023.